Our study revealed that TACC3 was highly expressed in more than two-thirds of STS patients, and that greater expression was associated with higher FNCLCC grade, poorer tumor differentiation, increased mitotic counts, advanced AJCC stage, higher p53 expression, higher Ki-67 expression, and undergoing postoperative therapy. This evidence concerns the gene TP53 and telomere syndrome.